Ziprasidone should be avoided in patients with congenital long QT syndrome or a history of cardiac arrhythmias.
- TRADE NAME: Geodon (Pfizer)
- INDICATIONS: Schizophrenia, bipolar I disorder
- CLASS: Antipsychotic, Antipsychotic, atypical
- HALF-LIFE: 7 hours
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Acetylcholinesterase inhibitors, Alcohol, Alfuzosin, Amitriptyline, Amoxapine, Amphetamines, Antifungals, Arsenic, Artemether/Lumefantrine, Asenapine, Astemizole, Carbamazepine, Chloroquine, Ciprofloxacin, Citalopram, CNS depressants, Conivaptan, Dasatinib, Degarelix, Dolasetron, Dopamine agonists, Dopamine agonists, Dronedarone, Food, Gadobutrol, Ketoconazole, Lapatinib, Levodopa, Levofloxacin, Lithium, Methylphenidate, Metoclopramide, Moxifloxacin, Nilotinib, Pazopanib, Pimavanserin, Pimozide, QT prolonging agents, Quinagolide, Quinine, Ranolazine, St John's Wort, Telavancin, Telithromycin, Tetrabenazine, Thioridazine, Voriconazole, Vorinostat
- See adverse reactions attributed to class:
INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS
See full prescribing information for complete boxed warning.
Please login to view the rest of this drug profile.
Click on the DRUG REVIEW ARTICLE tab (above) to see a review of ziprasidone in the Taylor & Francis journal Expert Opinion on Drug Safety.
(Note that non-subscribers to the journal will only be able to see an abstract of the article.)
Page last updated 08/22/2024
